Drugs /

mrg002

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-HER2/MMAE ADC MRG002 targets and binds to HER2 on the surface of tumor cells. Following internalization of MRG002, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.

Clinical Trials

View Clinical Trials for mrg002

Mrg002 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mrg002, 1 is phase 1/phase 2 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for mrg002 clinical trials.

Malignant solid tumor is the most common disease being investigated in mrg002 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mrg002
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mrg002 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mrg-002, mrg 002, anti-her2/mmae adc mrg002, adc mrg002, anti-her2/mmae antibody-drug conjugate mrg002
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C174205

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.